Sara Elizabeth Abbott, MD
- Assistant Professor, Pathology

Sara Elizabeth Abbott, MD
- Education
- BS, Duke University, 2003
- MA, Duke University, 2004
- MD, Case Western Reserve, 2012
- MS, Case Western Reserve, 2018
- Residency
- Anatomic Pathology & Clinical Pathology, Duke University Medical Center, 2016
- Fellowship
- Surgical Pathology, Duke University School of Medicine, 2017
- Oncology/Pathology, University Texas MD Anderson Hospital, 2018
- Positions
- Assistant Professor, Pathology
- Departments and Affiliations
- Pathology
Research
- Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES).. Mills AM, Peres LC, Meiss A, Ring KL, Modesitt SC, Abbott SE, Alberg AJ, Bandera EV, Barnholtz-Sloan J, Bondy ML, Cote ML, Funkhouser E, Moorman PG, Peters ES, Schwartz AG, Terry PD, Wallace K, Schildkraut JM. Int. J. Gynecol. Pathol. 2019 Mar; 38(2):157-170.
- Prospective Evaluation of Lymph Node Processing at Staging Surgery for High-grade Endometrial Cancer.. Davidson BA, Ehrisman J, Abbott S, Harmon Z, Secord AA, Berchuck A, Lee PS, Valea FA, Li X, Havrilesky LJ, Hall AHS. Int. J. Gynecol. Pathol. 2018 May; 37(3):252-255.
- Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies.. Peres LC, Risch H, Terry KL, Webb PM, Goodman MT, Wu AH, Alberg AJ, Bandera EV, Barnholtz-Sloan J, Bondy ML, Cote ML, Funkhouser E, Moorman PG, Peters ES, Schwartz AG, Terry PD, Manichaikul A, Abbott SE, Camacho F, Jordan SJ, Nagle CM, , Rossing MA, Doherty JA, Modugno F, Moysich K, Ness R, Berchuck A, Cook L, Le N, Brooks-Wilson A, Sieh W, Whittemore A, McGuire V, Rothstein J, Anton-Culver H, Ziogas A, Pearce CL, Tseng C, Pike M, Schildkraut JM, . Int J Epidemiol. 2018 04; 47(2):460-472.
- Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies.. Peres LC, Risch H, Terry KL, M Webb P, Goodman MT, Wu AH, Alberg AJ, Bandera EV, Barnholtz-Sloan J, Bondy ML, Cote ML, Funkhouser E, Moorman PG, Peters ES, Schwartz AG, Terry PD, Manichaikul A, Abbott SE, Camacho F, Jordan SJ, Nagle CM, , Anne Rossing M, Doherty JA, Modugno F, Moysich K, Ness R, Berchuck A, Cook L, Le N, Brooks-Wilson A, Sieh W, Whittemore A, McGuire V, Rothstein J, Anton-Culver H, Ziogas A, Pearce CL, Tseng C, Pike M, Schildkraut JM, . Int J Epidemiol. 2018 Mar;
- Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype.. Force J, Howie LJ, Abbott SE, Bentley R, Marcom PK, Kimmick G, Westbrook K, Sammons SL, Parks M, Topping DL, Emerson R, Broadwater G, Hyslop T, Blackwell KL, Nair SK. Clin. Breast Cancer. 2018 Oct; 18(5):410-417.